Literature DB >> 21070

Treatment of chronic schizophrenia.

D A Johnson.   

Abstract

The comprehensive treatment of schizophrenia requires the full resources of a clinical team that is able to offer treatment for the acute psychotic state in a hospital environment, and appropriate rehabilitation following resolution of the florid symptoms. Following a second or subsequent relapse, maintenance therapy with long-acting injections of depot antipsychotics will be required for an unknown period. Although drugs form an essential part of all treatments, it is essential to examine the environment for precipitating factors and to involve the patient's family in the rehabilitation. Recent studies have reported that some patients still have a relatively poor prognosis; although this proportion may be in the minority, the strain on the whole family of an even moderately handicapped patient can be enormous, and it is important to examine the needs of the whole family in evaluating care within the community. The effect of antipsychotic drugs is much wider that the mere control of acute symptoms and can influence the patterns of social behaviour and rehabilitation, in addition to offering protection against stress. The proper use of depot injections requires that they be kept under constant review. The current widespread practice of prescribing anti-cholinergic drugs on a prophylactic basis, or even as the inital treatment of extrapyramidal side-effects, needs revision.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 21070     DOI: 10.2165/00003495-197714040-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  59 in total

1.  Observations on the dose regime of fluphenazine decanoate in maintenance therapy ofschizophrenia.

Authors:  D A Johnson
Journal:  Br J Psychiatry       Date:  1975-05       Impact factor: 9.319

Review 2.  EFFECTS OF PSYCHOTROPIC DRUGS ON LONG-TERM ADJUSTMENT. A REVIEW.

Authors:  R K GITTELMAN; D F KLEIN; M POLLACK
Journal:  Psychopharmacologia       Date:  1964-04-03

3.  CHANGES IN SCHIZOPHRENIC PSYCHOPATHOLOGY AND WARD BEHAVIOUR AS A FUNCTION OF PHENOTHIAZINE TREATMENT.

Authors:  S C GOLDBERG; G L KLERMAN; J O COLE
Journal:  Br J Psychiatry       Date:  1965-02       Impact factor: 9.319

4.  The general practitioner and the schizophrenic patient.

Authors:  C M PARKES; G W BROWN; E M MONCK
Journal:  Br Med J       Date:  1962-04-07

5.  The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients.

Authors:  J Denham; L Adamson
Journal:  Acta Psychiatr Scand       Date:  1971       Impact factor: 6.392

6.  Influence of family life on the course of schizophrenic disorders: a replication.

Authors:  G W Brown; J L Birley; J K Wing
Journal:  Br J Psychiatry       Date:  1972-09       Impact factor: 9.319

7.  Do psyhiatric out-patients take their drugs?

Authors:  D R Willcox; R Gillan; E H Hare
Journal:  Br Med J       Date:  1965-10-02

8.  Antagonism of the antiavoidance effects of various agents by anticholinergic drugs.

Authors:  H M Hanson; C A Stone; J J Witoslawski
Journal:  J Pharmacol Exp Ther       Date:  1970-05       Impact factor: 4.030

9.  Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry.

Authors:  S R Hirsch; R Gaind; P D Rohde; B C Stevens; J K Wing
Journal:  Br Med J       Date:  1973-03-17

10.  Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels.

Authors:  L Rivera-Calimlim; H Nasrallah; J Strauss; L Lasagna
Journal:  Am J Psychiatry       Date:  1976-06       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.